Peptide

Crucial building blocks of life on Earth can more easily form in outer space – new research

Retrieved on: 
Thursday, April 18, 2024

Scientists believe life arose in a primordial soup of organic chemicals and biomolecules on the early Earth, eventually leading to actual organisms.

Key Points: 
  • Scientists believe life arose in a primordial soup of organic chemicals and biomolecules on the early Earth, eventually leading to actual organisms.
  • However, these complex molecules are assembled from a variety of small and simple molecules such as amino acids – the so-called building blocks of life.
  • This latest study sheds light on how some of these building blocks might have formed and assembled, and how they ended up on Earth.

Steps to life

  • Peptides can be made up of as little as two amino acids, but also range to hundreds of amino acids.
  • The assemblage of amino acids into peptides is an important step because peptides provide functions such as “catalysing”, or enhancing, reactions that are important to maintaining life.
  • However, despite their potentially important role in the origin of life, it was not so straightforward for peptides to form spontaneously under the environmental conditions on the early Earth.
  • Many of the building blocks of life such as amino acids, lipids and sugars can form in the space environment.
  • Because peptide formation is more efficient in space than on Earth, and because they can accumulate in comets, their impacts on the early Earth might have delivered loads that boosted the steps towards the origin of life on Earth.
  • So what does all this mean for our chances of finding alien life?
  • Once we know that, we’ll have a good idea of how widespread, or not, life might be.


Christian Schroeder does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Mblue Labs Discovers Anti-Aging Power In Methylene Blue, Launches Bluelene Face&Neck Remodel Mask

Retrieved on: 
Wednesday, March 13, 2024

Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.

Key Points: 
  • Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.
  • Mblue Labs, a woman and minority-owned business, is dedicated to advancing skincare science, and this latest product embodies their commitment to unparalleled innovation.
  • Methylene Blue penetrates skin cells at the mitochondrial level, creating cell health and proliferation.
  • To view an enhanced version of this graphic, please visit:
    The Face & Neck Remodel Mask features a powerful blend of the latest age-reversal ingredients, including Methylene Blue, Growth Factors, Advanced Peptides, and Niacinamide.

CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024

Retrieved on: 
Friday, April 5, 2024

Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.

Key Points: 
  • Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.
  • However, high levels of similar off-target peptides presented in healthy tissues make targeting the KK-LC-1/HLA-A*01 challenging.
  • CDR-Life’s data gathered on pMHC TCE antibodies with high specificity towards HLA-A*01 restricted KK-LC-1 epitopes demonstrate the antibodies’ promising anti-tumor activity and specificity for KK-LC-1/HLA-A*01 positive tumors.
  • In vitro studies showed significantly higher TCE-dependent T-cell activation towards cells presenting the target peptide compared to the risk peptides.

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 1, 2024

BURLINGTON, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, today reported its fourth quarter and full year 2023 financial results and provided a business update.

Key Points: 
  • “In addition, we expect to complete enrollment of our pivotal Revitalize-1 study and are excited to report topline data in the fourth quarter of 2024.
  • The Company expects to complete enrollment in the first half of 2024 and report topline data in the fourth quarter of 2024.
  • In December 2023, Fractyl presented preclinical findings in an oral presentation at the World Congress of Insulin Resistance Diabetes and Cardiovascular Disease 2023 Annual Meeting.
  • Cash Position: As of December 31, 2023, Fractyl had approximately $33.2 million in cash and cash equivalents.

Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors

Retrieved on: 
Thursday, March 28, 2024

DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine.

Key Points: 
  • DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine.
  • Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf.
  • CLINUVEL is now investing heavily in R&D with an ambitious clinical pipeline, including a phase III clinical trial for the pigment loss disorder vitiligo.
  • “German investors have been pivotal in supporting our work thus far and we hope to share our success with the wider investment community.”

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024

SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood
    SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • “We are thrilled by the results from the single ascending dose (SAD) portion of our clinical trial for BT-600.
  • During 2023, Biora reduced its outstanding notes by more than $80 million, resulting in a 75% reduction in net debt.
  • Comparison of Full-Year Ended December 31, 2023 and 2022
    Operating expenses were $67.1 million for the year ended December 31, 2023, compared to $62.1 million for the year ended December 31, 2022.

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Retrieved on: 
Monday, April 8, 2024

Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.

Key Points: 
  • Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.
  • “Our data illustrate that we can repeatedly generate TCEs that maximize tumor-cell killing without inducing excessive cytokine release.
  • The data show that AbCellera’s IgG and heavy chain-only CD28-binding antibodies do not display superagonist activity — a property associated with toxicity.
  • “We look forward to advancing these programs with the aim of delivering powerful new medicines for patients.”

Woman- and Minority-Owned Beauty Brand Launches Keya Skincare Line

Retrieved on: 
Monday, April 8, 2024

CLIFTON, N.J., April 8, 2024 /PRNewswire/ -- By Kaycee's, a visionary woman-owned beauty brand at the forefront of innovation, proudly unveils its highly anticipated Keya skincare product line, signaling a new era of beauty excellence.

Key Points: 
  • CLIFTON, N.J., April 8, 2024 /PRNewswire/ -- By Kaycee's, a visionary woman-owned beauty brand at the forefront of innovation, proudly unveils its highly anticipated Keya skincare product line, signaling a new era of beauty excellence.
  • "We are thrilled to introduce Keya, our new skincare line, which embodies our core values of integrity, efficacy, and sustainability," said Ketki Yagnik, Founder and CEO of By Kaycee's.
  • To celebrate the launch of its groundbreaking Keya skincare collection, By Kaycee's invites beauty enthusiasts to embark on a transformative journey of self-discovery.
  • "The Keya skincare line represents a new paradigm in beauty—a fusion of science, nature, and innovation," said Yagnik.

Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

Retrieved on: 
Monday, April 8, 2024

CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director.

Key Points: 
  • O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries
    CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director.
  • O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and pharmaceutical industries.
  • "That's just the start as Invaio pioneers a new approach in agriculture by combining novel active ingredients and delivery systems.
  • "I have been impressed with Invaio's technologies and capabilities and am excited to join the team," said Amy O'Shea, Flagship Pioneering CEO-Partner and Invaio CEO and Board Director.

IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service

Retrieved on: 
Monday, April 8, 2024

PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network.

Key Points: 
  • The Ginkgo Technology Network is a groundbreaking global ecosystem of cutting-edge technology partners dedicated to driving innovation in customer R&D programs.
  • Ginkgo plans to integrate the technological capabilities of its network partners to provide customers with more robust end-to-end solutions to drive successful R&D outcomes across biological end markets.
  • IdeeLab is leading sustainable agriculture biological products development in Brazil by developing new technologies on behalf of customers for the crop input market.
  • Anna Marie Wagner, Ginkgo's SVP, Head of AI and Corporate Development: "IdeeLab has been inspiring a new era in Brazilian agriculture and we're thrilled to welcome them to the Ginkgo Technology Network!